medigraphic.com
Colegio de Medicina Interna de México.

2005, Number 2

<< Back Next >>

Med Int Mex 2005; 21 (2)

Endocrine, metabolic and genetic aspects of endothelial dysfunction and its relation to visceral obesity

Bastarrachea SRA, Castro MG, Laviada MH, Yza VR, Llamas EG, Comuzzie AG

Language: Spanish
References: 76
Page: 133-153
PDF size: 119.15 Kb.


ABSTRACT

Atherosclerosis is the combination of pathological changes that not only affect cells deposited along the walls of the arteries, but also the inflammatory ones. Stimulus implied in the cause of atherosclerosis, which include LDL, mechanical forces followed by high blood pressure, and inflammatory response induced by metabolic and hemodynamic aspects as risk factors, are diverse. Resistance to insulin, followed by visceral obesity and diabetes mellitus type 2 represent equally chronic and complex systemic alterations. Thus, it is not strange that the intersection of these disorders and their final outcomes cause atherosclerotic diabetes. This article reviews the endocrine, metabolic and genetic aspects of endothelial dysfunction and its relation with visceral obesity.


REFERENCES

  1. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.

  2. Adler AI, Stratton IM, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.

  3. UKPDS Group. Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23). BMJ 1998;316:823-8.

  4. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.

  5. Rolka DB, Narayan KM, Thompson TJ, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2002;25(2):413.

  6. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101(9):975-80.

  7. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103(2):152-62.

  8. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41(6):715-22.

  9. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20(2):538-44.

  10. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952-57.

  11. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95(1):69-75.

  12. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279(24):1955-61.

  13. Howard G, O’Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) investigators. Circulation 1996;93(10):1809-17.

  14. Haffner SM, D’Agostino R Jr, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22(4):562-8.

  15. Festa A, D’Agostino R Jr, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999;19(3):562-8.

  16. Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102(1):42-47.

  17. Raskin P, Rappaport EB, Cole ST, et aI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43(3):278-84.

  18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-97.

  19. Reaven GM. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev 1993;9(Suppl 1):5S-12S.

  20. Groop LC, Widen E, Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 1993;36(12):1326-31.

  21. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45(5):633-38.

  22. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999;111(3): 241-48.

  23. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103(2):253-9.

  24. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23(8):1067-71.

  25. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133(4):263-74.

  26. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989;38(12):1512-27.

  27. Lebovitz HE. Type 2 diabetes: an overview. Clin Chem 1999;45(8Pt2):1339-45.

  28. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981;70(3):579-88.

  29. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63(13):1373-405.

  30. Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA, et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2001;286(4):735-41.

  31. Rakugi H, Kamide K, Ogihara T. Vascular signaling pathways in the metabolic syndrome. Curr Hypertens Rep 2002;4(2):105-11.

  32. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002;26(Suppl2):S28-38.

  33. Bakker SJ, Serne EH, Ter-Wee PM, Donker AJ, Gans RO. Insulin’s acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin’s acute effects on proximal tubular sodium reabsorption correlation with salt sensitivity in normal subjects. Nephrol Dial Transplant 1999;14(10):2357-63.

  34. Hirschler V, Aranda C, Oneto A, Gonzalez C, Jadzinsky M. Is acanthosis nigricans a marker of insulin resistance in obese children? Diabetes Care 2002;25(12):2353.

  35. Bernard L, Christin-Maitre S, Basille C, Chabbert-Buffet N. Insulin resistance and polycystic ovary syndrome. Gynecol Obstet Fertil 2003;31(2):109-16.

  36. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65.

  37. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338(13):867-72.

  38. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134(1):61-71.

  39. Ross R. Atherosclerosis: an inflammatory disease. NEJM 1999;340:115-26.

  40. Vogel RA. Cholesterol lowering and endothelial function. Am J Med 1999;107(5):479-87.

  41. Despres JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994;8(3):629-58.

  42. Zaman AG, Helft G, Osende JI, Fuster V, Badimon JJ. Histopathology and pathogenesis of plaque instability and thrombus formation. Drugs Today (Barc) 1999;35(8):641-56.

  43. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85(8):753-66.

  44. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997;100(11Suppl):S61-65.

  45. Smith JD, Dansky HM, Breslow JL. Genetic modifiers of atherosclerosis in mice. Ann NY Acad Sci 2001;947:247-52,252-53.

  46. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24(3):588-97.

  47. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19(1):73-82.

  48. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003;(134):10-17.

  49. The HOPE. Heart Outcomes Prevention Evaluation Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol 1996;12(2):127-37.

  50. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002;18(Suppl 3):S82-85.

  51. Dzau VJ, Gibbons GH, Mann M, Braun-Dullaeus R. Future horizons in cardiovascular molecular therapeutics. Am J Cardiol 1997;80(9A):33I-39I.

  52. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001;21(12):1891-95.

  53. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7(1):161-71.

  54. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106(6):679-84.

  55. Greenberg AS. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. J Diabetes Complications 2003;17(4):218-28.

  56. Black PH. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003;17(5):350-64.

  57. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43.

  58. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002;23(11):831-4.

  59. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003;24(6):327-4.

  60. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000;343(16):1179-82.

  61. Libby P. Atheroma: more than mush. Lancet 1996;348(Suppl 1):s4-7.

  62. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343(16):1139-47.

  63. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343(16):1148-55.

  64. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331(7):417-24.

  65. Ryan J, Ward MF, Sama AE. C-reactive protein and serum amyloid A protein in unstable angina. N Engl J Med 1995;332(6):398-99; author reply 399-400.

  66. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97(20):2007-11.

  67. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130(11):933-37.

  68. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51(5):1596-600.

  69. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999;100(3):230-5.

  70. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103(9):1194-97.

  71. Muller-Wieland D, Knebel B, Avci H, Lehr S, Laudes M, Ristow M, et al. Insulin-regulated transcription factors: molecular link between insulin resistance and cardiovascular risk factors. Int J Obes Relat Metab Disord 2001;25(Suppl 1):S35-37.

  72. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999;258(2):431-35.

  73. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102(1):42-47.

  74. Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial. Circulation 1996;94(5):946-51.

  75. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327-34.

  76. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia1998;41(10):1241-8.




2020     |     www.medigraphic.com